At Antiverse, we are engineering the future of drug discovery. 

We have developed an Artificial Intelligence (AI)-powered de novo drug discovery platform, which uses hyper-expressing cell lines and machine learning to design antibodies against various targets. Our technology facilitates the development of antibodies capable of binding challenging drug targets, including G-protein coupled receptors (GPCRs) and ion channels, over a 6-month timeline.

We are passionate about what we do and the impact our discoveries have on patients across the globe. Based in Cardiff, our expert team spans structural biology, machine learning and medicine - and together, we are catalysing the next shift in AI-augmented drug discovery. 

Accelerate@Babraham

UK Innovation & Science Seed Fund

Kadmos Capital

Tensor Ventures

Tomorrow Scale

Innospark Ventures

Deep Science Ventures

Development Bank of Wales

AngelHub

Ed Parkinson

Wren Capital

Cambridge Angels group

SyndicateRoom

Future Planet Capital

ACF Investors

Antiverse

Join EngBioX on 6th Dec as we unveil our expanded fund in engineering biology, tackling global challenges head-on.

From groundbreaking startups to major deals with pharma giants, we're investing in innovation.

Hear firsthand from CellCentric, backed by UKI2S, on how they secured a game-changing pharma deal and are developing medicines in late-stage clinical trials.

Dive into a panel discussion with CEOs, exploring innovative business models powered by UKI2S including: Pencil Biosciences Limited gene editing, twig's industrial biotech, and Antiverse's AI biotech are transforming the game!

📅 6th Dec 2023
🕔 5:00 PM – 7:00 PM
📍 Cambridge 

Find out more and register your interest👇

https://lnkd.in/eEm36wAD

#UKI2S #VentureCapital #Investment #EngBio Future Planet Capital

Next week we are in Bristol for an engaging BioTuesday that will spotlight the latest innovations in TechBio 🚀

TechBio represents a burgeoning field of data-driven research, where biotech companies leverage cutting-edge techniques that integrate hardware and software to revolutionise drug discovery and patient care.

The evening will feature a comprehensive introduction to the TechBio landscape, exploring the potential impact of this unique research area on life sciences, as well as a regional funding update, and a showcase of five early-stage companies focusing on TechBio: éclateral, Milbotix, FluoretiQ Limited, EarSwitch and Antiverse ⚡

Admission to this event is complimentary for OBN members, academics, students, and research scientists, while a nominal fee applies to non-OBN members. Book now: https://lnkd.in/euCvVZJU

#lifesciences #southwest #biotech #techbio

Meet with Antiverse at #BioEurope in Munich, Germany, this November 🇩🇪

Connect with us here: https://hubs.la/Q026JQxD0 

Antiverse enables the design of antibodies against historically challenging and neglected drug targets, like #GPCR receptors and ion channels. We combine machine learning to design 'target-specific' libraries with hyper-expressing engineered cell lines to augment the discovery process. 

Visit our website to find out more: https://hubs.la/Q026JWm80

Biotechnology Innovation Organization EBD Group #biotechnology #pharma #pharmapartnering 

Last week, we had the privilege of hosting Tommy Tang, Director of Computational Biology at Immunitas Therapeutics on our latest live episode for the Future of Drug Discovery podcast 🤖🎙️

Link to the full recording 🔗 https://hubs.la/Q0263HWq0 

We had a fantastic conversation with Tommy. He has an incredibly inspiring career in computational biology, which started with self-teaching bioinformatics skills in his spare time💡

If you're a researcher looking to switch to computational biology, or just looking for a weekly refuel of motivation, we highly recommend listening to the full recording, now available on all major podcast platforms!

#FODD #drugdiscovery #immunooncology #computationalbiology 

Thank you to Sifted for featuring Antiverse as one of the top 5 European startups to watch in 2023 in cancer tech! 🎉

Difficult-to-drug targets, like #GPCR receptors, have strong links to #oncology. Antiverse is dedicated to opening up the druggable antibody space for these targets to improve cancer survival prospects. 

Read the full briefing 🔗 https://hubs.la/Q0263GTx0

#antibodydiscovery #drugdiscovery #machinelearning

Font Awesome

Organization Schema

PostalAddress Schema

Ruby on Rails Token

Place Schema

Cloudflare Blocked

Rack Cache

JobPosting Schema

Australian Server Location

section.io

Co-Founder & CEO

Murat Tunaboylu

Engineering

Andrew Moyes

Co-Founder & CTO

Ben Holland

Matt Fates

Co-founder and CEO

Co-founder and CTO

Companies With Less Than $500M in Revenue (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Companies With More Than $1M in Revenue (Top 10K)

Europe, Middle East, and Africa (EMEA) Seed Stage Companies With Fewer Than 50 Employees (Top 10K)

Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people's lives.

i&i Biotech Fund

Seed Round - Antiverse

VentureOut

Non Equity Assistance - Antiverse

Funding Round - Antiverse

Grant - Antiverse

Pre Seed Round - Antiverse

Cardiff

United Kingdom

Europe

Financings for November 12, 2024

Financings for Nov. 6, 2024

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Antiverse: £3.5 Million Raised For Advancing GenAI-Based Antibody Design Platform

Antiverse Raises £3.5M in Seed Funding

Lattice to Release HRIS for General Availability at Fall Conference, Lattiverse

Yposkesi A Plug-and-Play Adeno-Associated Virus Platform

Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics

All news articles for October 2023

United States

North America

India

Asia

Antiverse is a company that provides a website for users to access and improve their user experience. They collect and use personal data to enhance the user experience.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	f44219ca
crunchbase profile	general	Nov 22, 2024 9:06 AM	5cc7e6ed
li profile	general	Dec 1, 2023 11:02 AM	05d5e6e9
translate crunchbase fundingrounds	general	Nov 22, 2024 1:51 PM	f1dfbe00
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

IO:ANTIVERSE

Antiverse